MA27318A1 - Comprime de lasofoxifene et son enrobage - Google Patents

Comprime de lasofoxifene et son enrobage

Info

Publication number
MA27318A1
MA27318A1 MA28036A MA28036A MA27318A1 MA 27318 A1 MA27318 A1 MA 27318A1 MA 28036 A MA28036 A MA 28036A MA 28036 A MA28036 A MA 28036A MA 27318 A1 MA27318 A1 MA 27318A1
Authority
MA
Morocco
Prior art keywords
lasofoxifene
coating
active ingredient
tablet
compositions
Prior art date
Application number
MA28036A
Other languages
English (en)
Inventor
Daniel Scott Gierer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27318A1 publication Critical patent/MA27318A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 10 Juillet 2002 60/395,090 Comprimé de lasofoxifène et son enrobage Des compositions pharmaceutiques ayant une distribution et activité uniformes de médicament, utilisant du lasofoxifène comme ingrédient actif et contenant un dioxyde de silicium pour réduire la perte d'ingrédient actif au cours du procédé de production, ainsi que des procédés pour la production de ces compositions sont décrits. La triacétine d'enrobage, servant de plastifiant, se révèle conférer une bonne stabilité au lasofoxifène.
MA28036A 2002-07-10 2005-01-10 Comprime de lasofoxifene et son enrobage MA27318A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39509002P 2002-07-10 2002-07-10

Publications (1)

Publication Number Publication Date
MA27318A1 true MA27318A1 (fr) 2005-05-02

Family

ID=30115812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28036A MA27318A1 (fr) 2002-07-10 2005-01-10 Comprime de lasofoxifene et son enrobage

Country Status (36)

Country Link
US (2) US20040057992A1 (fr)
EP (1) EP1534248B1 (fr)
JP (2) JP4446446B2 (fr)
KR (1) KR100782693B1 (fr)
CN (1) CN100344278C (fr)
AP (1) AP2005003201A0 (fr)
AR (1) AR040434A1 (fr)
AT (1) ATE550017T1 (fr)
AU (1) AU2003247017B2 (fr)
BR (1) BR0312563A (fr)
CA (1) CA2489407C (fr)
CY (1) CY1112892T1 (fr)
DK (1) DK1534248T3 (fr)
EA (1) EA007268B1 (fr)
EC (1) ECSP055528A (fr)
ES (1) ES2395123T3 (fr)
HK (1) HK1077747A1 (fr)
HN (1) HN2003000206A (fr)
HR (1) HRP20041196A2 (fr)
IL (2) IL165746A0 (fr)
IS (1) IS7594A (fr)
MA (1) MA27318A1 (fr)
MX (1) MXPA05000394A (fr)
NO (1) NO20050018L (fr)
NZ (1) NZ537278A (fr)
OA (1) OA12883A (fr)
PA (1) PA8576201A1 (fr)
PE (1) PE20040104A1 (fr)
PL (1) PL374913A1 (fr)
PT (1) PT1534248E (fr)
SI (1) SI1534248T1 (fr)
TN (1) TNSN05006A1 (fr)
TW (1) TW200406222A (fr)
UY (1) UY27886A1 (fr)
WO (1) WO2004006895A1 (fr)
ZA (1) ZA200410196B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1871359A1 (fr) * 2005-04-07 2008-01-02 Miso Sabovic Retardement du processus de vieillissement et des troubles provoques par le vieillissement
WO2006118137A1 (fr) * 2005-04-26 2006-11-09 Dainippon Sumitomo Pharma Co., Ltd. Préparation granulaire contenant un dérivé de biguanide
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP3173084B1 (fr) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Dérivés de quinazoline pour le traitement de cancers
LT2487166T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
CA2835910C (fr) * 2007-04-25 2016-06-28 Warner Chilcott Company, Llc Uniformite amelioree de contenu de vitamine d dans des formes dosifiees pharmaceutiques
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
CN101820863A (zh) * 2007-10-10 2010-09-01 马林克罗特贝克公司 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途
WO2009135067A1 (fr) * 2008-05-01 2009-11-05 Wyeth Formulations de vernis pharmaceutique
SG190618A1 (en) * 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
US9545381B2 (en) * 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
RU2661402C2 (ru) * 2011-10-17 2018-07-16 Лексикон Фармасьютикалз, Инк. Твердые дозированные формы (s)-этил 2-амино-3-(4-(2-амино-6((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата
DK2851075T3 (da) 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
PL3043778T3 (pl) * 2013-09-13 2018-04-30 Bayer Pharma Aktiengesellschaft Kompozycje farmaceutyczne zawierające refametinib
RU2539375C1 (ru) * 2013-11-07 2015-01-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
US20190183850A1 (en) * 2016-07-25 2019-06-20 Canopy Growth Corporation New cannabis tablet formulations and compositions and methods of making the same
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Er+乳がんのラソフォキシフェン処置
EP3773524A4 (fr) 2018-04-10 2021-12-22 Duke University Traitement du cancer du sein avec du lasofoxifène
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN114288258A (zh) * 2022-02-18 2022-04-08 山东新时代药业有限公司 一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182A (en) * 1845-09-09 Island
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6372457B1 (en) 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
KR200161927Y1 (ko) * 1997-08-26 1999-12-01 윤종용 냉장고
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (fr) * 2000-03-10 2001-11-14 Pfizer Products Inc. Utilisation d'un sel ferreux pour l'inhibition de la dégradation oxydative de compositions pharmaceutiques
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
OA12596A (en) * 2001-05-01 2006-06-08 Pfizer Prod Inc Method for manufacturing a low dose pharmaceuticalcomposition.
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Also Published As

Publication number Publication date
OA12883A (en) 2006-09-15
EA200401583A1 (ru) 2005-06-30
PA8576201A1 (es) 2004-05-26
HK1077747A1 (en) 2006-02-24
MXPA05000394A (es) 2005-03-23
PL374913A1 (en) 2005-11-14
ECSP055528A (es) 2005-03-10
DK1534248T3 (da) 2012-06-25
SI1534248T1 (sl) 2012-07-31
NZ537278A (en) 2007-07-27
EP1534248B1 (fr) 2012-03-21
CY1112892T1 (el) 2016-04-13
IL165746A (en) 2008-12-29
US20040057992A1 (en) 2004-03-25
TW200406222A (en) 2004-05-01
JP2005535671A (ja) 2005-11-24
CA2489407A1 (fr) 2004-01-22
AU2003247017B2 (en) 2008-03-06
IL165746A0 (en) 2006-01-15
NO20050018L (no) 2005-01-12
ES2395123T3 (es) 2013-02-08
ZA200410196B (en) 2006-07-26
PE20040104A1 (es) 2004-02-27
WO2004006895A1 (fr) 2004-01-22
CN1668285A (zh) 2005-09-14
AR040434A1 (es) 2005-04-06
EP1534248A1 (fr) 2005-06-01
PT1534248E (pt) 2012-05-25
AP2005003201A0 (en) 2005-03-31
US20070110800A1 (en) 2007-05-17
JP4446446B2 (ja) 2010-04-07
KR100782693B1 (ko) 2007-12-07
US7553500B2 (en) 2009-06-30
ATE550017T1 (de) 2012-04-15
CN100344278C (zh) 2007-10-24
AU2003247017A1 (en) 2004-02-02
CA2489407C (fr) 2009-01-27
IS7594A (is) 2004-12-13
KR20050017102A (ko) 2005-02-21
JP2007031451A (ja) 2007-02-08
EA007268B1 (ru) 2006-08-25
TNSN05006A1 (fr) 2007-05-14
UY27886A1 (es) 2004-02-27
HN2003000206A (es) 2004-07-27
HRP20041196A2 (en) 2005-04-30
BR0312563A (pt) 2005-04-19

Similar Documents

Publication Publication Date Title
MA27318A1 (fr) Comprime de lasofoxifene et son enrobage
MA27017A1 (fr) Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuses uniformes
UA84726C2 (ru) Производные простагландинов, способ их получения, фармацевтическая композиция (варианты) и способ лечения глаукомы или гипертензии глаза
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
CR20240093A (es) Inhibidores de NLRP3
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
WO2004108162A3 (fr) Composition pharmaceutique et methode de traitement
WO2004055006A8 (fr) Nouveaux composes presentant un effet inhibiteur selectif de la gsk3
WO2003082853A8 (fr) Nouveaux composes
EP1283054A4 (fr) Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
CA2214026A1 (fr) Compositions pharmaceutiques comprenant des inhibiteurs de la monoamine oxydase b
DK1383540T3 (da) Fremgangsmdåer og farmaceutiske sammensætninger til sårheling
WO2006053089A3 (fr) Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
SE0102440D0 (sv) New compound
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
HUP0203338A2 (hu) Integrin receptor ligandumok
TW200517127A (en) Novel composition
HUP0300191A2 (hu) 2,6-Diamino-6-metil-heptánsav és származékai, eljárás ezek előállítására és alkalmazásuk
UA86767C2 (ru) АЗАИНДОЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ ФАКТОРА Ха
BG108151A (en) Caloporoside derivatives, methods for the production thereof and their use
GR1010670B (el) Φαρμακευτικη συνθεση που περιεχει απιξαβανη και μεθοδος παρασκευης αυτης